Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Published 19 November 2008, doi:10.1136/bmj.a2585
Cite this as: BMJ 2008;337:a2585
| The first 150 words of the full text of this article appear below. |
In asking "Does this work for you?"1 Christakis finds the heart of evidence based medicine—"the conscientious, explicit and judicious use of current best evidence in making decisions about the care of individual patients."2 The individual approach can also reconcile clinical trial results with the demands of clinical practice: "managers and trialists may be happy for treatments to work on average; patients expect their doctors to do better than that."3
That not all patients achieve great benefit and need an individualised approach has been shown in treating depression4 and is particularly true for pain.
In acute pain, patients either have very good or very poor pain relief with non-steroidal anti-inflammatory drugs. In neuropathic pain fewer than half of patients commonly achieve adequate pain relief with any treatment. In migraine the proportion of patients achieving rapid and prolonged pain relief (adjusted for the placebo response) is only about 25%. With TNF-antagonists in
Andrew Moore, senior research fellow1, Sebastian Straube, academic foundation year 2 doctor1, Sheena Derry, research associate1, Henry McQuay, Nuffield professor of clinical anaesthetics1
1 Pain Research and Nuffield Department of Anaesthetics, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DU
andrew.moore@pru.ox.ac.uk